Strides Pharma Science Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2024 • Pharma: 100.0%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Promoters have been increasing their shareholding - up 2.1pp over 2 years
- Latest quarter profit grew 56.7% YoY, showing strong momentum
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 2.49x)
- Operating margins have improved to 11.9% from 8.3%
- Company generates healthy free cash flow
- Institutional investors have been accumulating - FII+DII up 2.5pp
CONS
- A large part of profit comes from other income (34.6% of PBT)
- Recurring exceptional / one-off items are inflating headline profit
- Company has delivered a poor sales growth of 7.9% over past five years
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| STAR | 1186.10 | 17.82 | 10932.61 | 0.42 | 165.49 | 56.73 | 1265.41 | 13.01 | 18.57 | 18.06 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 930 | 999 | 1,006 | 1,044 | 1,054 | 1,167 | 1,154 | 1,190 | 1,120 | 1,221 | 1,195 | 1,323 | 1,265 | |
| 763 | 846 | 864 | 839 | 864 | 982 | 943 | 973 | 902 | 989 | 959 | 1,084 | 1,133 | |
| Operating Profit | 167 | 153 | 142 | 204 | 190 | 185 | 210 | 218 | 218 | 232 | 236 | 240 | 133 |
| OPM % | 17.91% | 15.32% | 14.12% | 19.58% | 18.02% | 15.82% | 18.23% | 18.30% | 19.48% | 18.97% | 19.75% | 18.11% | 10.50% |
| 3 | -129 | -1 | -22 | 111 | 25 | 3 | -15 | 0 | 18 | 104 | 2 | -58 | |
| Interest | 76 | 79 | 70 | 71 | 73 | 74 | 52 | 50 | 47 | 46 | 43 | 42 | 41 |
| Depreciation | 60 | 60 | 49 | 48 | 47 | 48 | 48 | 49 | 49 | 50 | 51 | 53 | 56 |
| Profit before Tax | 33 | -115 | 22 | 64 | 182 | 87 | 113 | 103 | 122 | 154 | 246 | 147 | 200 |
| Tax % | 29.11% | 6.49% | 73.19% | 19.67% | 10.45% | 16.05% | 21.09% | 20.11% | 13.49% | 14.00% | 15.21% | 12.80% | 17.09% |
| Net Profit | 0 | 0 | 0 | 0 | 683 | 94 | 90 | 86 | 106 | 132 | 208 | 129 | 165 |
| -0.79 | -14.54 | -1.22 | 2.60 | 17.77 | 7.81 | 9.56 | 8.92 | 10.81 | 13.84 | 21.93 | 13.77 | 17.02 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2,755 | 2,845 | 2,178 | 2,752 | 3,316 | 3,070 | 3,688 | 3,890 | 4,565 | 4,859 | 5,004 | |
| 2,228 | 2,443 | 1,936 | 2,236 | 2,689 | 3,092 | 3,303 | 3,318 | 3,768 | 4,014 | 4,164 | |
| Operating Profit | 527 | 402 | 242 | 516 | 627 | -22 | 385 | 572 | 798 | 845 | 840 |
| OPM % | 19.14% | 14.14% | 11.12% | 18.75% | 18.90% | -0.70% | 10.45% | 14.71% | 17.47% | 17.38% | 16.79% |
| 125 | 45 | 62 | -25 | 103 | -110 | 118 | -139 | 128 | 205 | 65 | |
| Interest | 183 | 196 | 79 | 156 | 150 | 177 | 261 | 280 | 249 | 179 | 172 |
| Depreciation | 126 | 154 | 117 | 174 | 206 | 233 | 243 | 214 | 192 | 202 | 210 |
| Profit before Tax | 343 | 80 | 62 | 55 | 275 | -653 | -286 | -115 | 487 | 669 | 746 |
| Tax % | 18.48% | 7.11% | -43.04% | 20.71% | 11.49% | 27.32% | 19.32% | -25.36% | 15.92% | 14.08% | 14.99% |
| Net Profit | 280 | 74 | 89 | 43 | 244 | -474 | -231 | -144 | 409 | 575 | 634 |
| EPS | 44.64 | 74.23 | 36.24 | 4.06 | 29.92 | -51.28 | -22.49 | -7.68 | 389.90 | 60.34 | — |
| Dividend Payout % | 10.07% | 2.69% | 8.28% | 344.56% | 8.35% | 0.00% | -6.68% | -32.54% | 1.03% | 8.29% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 5%
- 5 Years:
- 8%
- 3 Years:
- 10%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 18%
- 5 Years:
- 16%
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- 30%
RETURN ON EQUITY
- 10 Years:
- 3%
- 5 Years:
- 1%
- 3 Years:
- 10%
- Last Year:
- 20%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 89 | 90 | 90 | 90 | 90 | 90 | 90 | 92 | 92 | 92 |
| Minority Interest | 134 | 155 | 153 | 67 | 37 | 24 | -39 | -54 | 35 | 42 |
| 2,651 | 2,365 | 2,552 | 2,432 | 2,682 | 2,267 | 2,103 | 2,031 | 2,459 | 3,015 | |
| 4,126 | 2,922 | 3,671 | 2,285 | 2,391 | 3,034 | 2,989 | 2,380 | 1,774 | 1,675 | |
| Trade Payables | 774 | 712 | 889 | 798 | 1,134 | 1,072 | 982 | 852 | 1,032 | 1,310 |
| 261 | 342 | 453 | 281 | 483 | 275 | 249 | 272 | 387 | 510 | |
| Total Liabilities | 8,035 | 6,585 | 7,807 | 5,953 | 6,817 | 6,761 | 6,373 | 5,572 | 5,780 | 6,643 |
| 2,909 | 2,903 | 3,570 | 2,026 | 2,151 | 2,333 | 2,298 | 1,853 | 1,888 | 2,100 | |
| Capital Work in Progress | 204 | 322 | 100 | 148 | 228 | 56 | 48 | 80 | 100 | 161 |
| 1,525 | 588 | 702 | 549 | 697 | 540 | 490 | 303 | 409 | 291 | |
| 733 | 552 | 874 | 783 | 1,201 | 1,174 | 1,147 | 1,126 | 1,278 | 1,635 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,142 | 1,203 | 1,289 | |
| Cash & Bank | 329 | 303 | 517 | 237 | 180 | 187 | 316 | 191 | 137 | 213 |
| 2,334 | 1,917 | 2,045 | 2,210 | 2,360 | 2,470 | 2,074 | 877 | 765 | 954 | |
| Total Assets | 8,035 | 6,585 | 7,807 | 5,953 | 6,817 | 6,761 | 6,373 | 5,572 | 5,780 | 6,643 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 347 | 241 | 116 | 250 | 325 | -260 | -43 | 701 | 684 | 703 | |
| Cash from Investing | -687 | 583 | -148 | 1,306 | -521 | -119 | 302 | -150 | -90 | -173 |
| Cash from Financing | 338 | -1,016 | 194 | -1,709 | -16 | 421 | -214 | -693 | -643 | -453 |
| -60 | -246 | 106 | -199 | -55 | 45 | 133 | -143 | -48 | 76 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-11 - Strides Pharma Science Limited has informed the Exchange about completion of USFDA Inspection at the Company s Formulations Facility at Alathur
2026-08-19 - Strides Pharma Science Limited has informed the Exchange regarding a press release dated August 19, 2026, titled "Strides receives USFDA Establishment Inspection Report (EIR) for flagship facility in Bengaluru".
2026-08-18 - Strides Pharma Science Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 14, 2026. Further, the company has informed the Exchange regarding voting results.
2026-08-14 - Strides Pharma Science Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 14, 2026
2026-08-03 - Strides Pharma Science Limited has informed the Exchange about Transcript of Earnings Call pertaining to Unaudited Financial Results of the Company for the quarter ended June 30, 2026.
2026-08-01 - Strides Pharma Science Limited has informed the Exchange about Copy of Newspaper Publication- Unaudited Financial Results for the quarter ended June 30, 2026
2026-07-31 - Strides Pharma Science Limited has informed the Exchange about the link for Earnings Call pertaining to unaudited financial results for Q1 FY27
2026-07-31 - Strides Pharma Science Limited has informed the Exchange about Investor Presentation for Earnings call on Q1 FY 2027
2026-07-31 - Strides Pharma Science Limited has informed the Exchange regarding a press release dated July 31, 2026, titled "Strides Delivers Steady Performance with Q1FY27; Revenue at ₹12,654m, Grew 13% YoY; Ex-US Markets Grew 17% YoY".
News
Recent coverage and analyst commentary for STAR
Loading news…
AI Stock Analyst
Strides Pharma Science Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account